Trial · NCT01571635
Results by group130
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 130
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Potential Recommended Dose as Determined by Number of Participants Experiencing Dose-Limiting Toxicities and Recommended Dose | Dose Level 1a: 0.1 mg/kg | 0 | Participants | ||
| Potential Recommended Dose as Determined by Number of Participants Experiencing Dose-Limiting Toxicities and Recommended Dose | Dose Level 1b: 0.3 mg/kg | 0 | Participants | ||
| Potential Recommended Dose as Determined by Number of Participants Experiencing Dose-Limiting Toxicities and Recommended Dose | Dose Level 2: 0.5 mg/kg | 0 | Participants | ||
| Potential Recommended Dose as Determined by Number of Participants Experiencing Dose-Limiting Toxicities and Recommended Dose | Dose Level 3: 0.75 mg/kg | 0 | Participants | ||
| Potential Recommended Dose as Determined by Number of Participants Experiencing Dose-Limiting Toxicities and Recommended Dose | Dose Level 4: 1 mg/kg | 0 | Participants | ||
| Number of Participants With Red Blood Cell Transfusion Burden Reduction From Baseline During Treatment | Dose Level 1a: 0.1 mg/kg | ≥ 25% reduction | 0 | Participants | |
| Number of Participants With Red Blood Cell Transfusion Burden Reduction From Baseline During Treatment | Dose Level 1b: 0.3 mg/kg | ≥ 25% reduction | 0 | Participants | |
| Number of Participants With Red Blood Cell Transfusion Burden Reduction From Baseline During Treatment | Dose Level 2: 0.5 mg/kg | ≥ 25% reduction | 2 | Participants | |
| Number of Participants With Red Blood Cell Transfusion Burden Reduction From Baseline During Treatment | Dose Level 3: 0.75 mg/kg | ≥ 25% reduction | 4 | Participants | |
| Number of Participants With Red Blood Cell Transfusion Burden Reduction From Baseline During Treatment | Dose Level 4: 1 mg/kg | ≥ 25% reduction | 3 | Participants | |
| Number of Participants With Red Blood Cell Transfusion Burden Reduction From Baseline During Treatment | Dose Level 1a: 0.1 mg/kg | ≥ 33% reduction | 0 | Participants | |
| Number of Participants With Red Blood Cell Transfusion Burden Reduction From Baseline During Treatment | Dose Level 1b: 0.3 mg/kg | ≥ 33% reduction | 0 | Participants | |
| Number of Participants With Red Blood Cell Transfusion Burden Reduction From Baseline During Treatment | Dose Level 2: 0.5 mg/kg | ≥ 33% reduction | 2 | Participants | |
| Number of Participants With Red Blood Cell Transfusion Burden Reduction From Baseline During Treatment | Dose Level 3: 0.75 mg/kg | ≥ 33% reduction | 3 | Participants | |
| Number of Participants With Red Blood Cell Transfusion Burden Reduction From Baseline During Treatment | Dose Level 4: 1 mg/kg | ≥ 33% reduction | 1 | Participants | |
| Number of Participants With Red Blood Cell Transfusion Burden Reduction From Baseline During Treatment | Dose Level 1a: 0.1 mg/kg | ≥ 50% reduction | 0 | Participants | |
| Number of Participants With Red Blood Cell Transfusion Burden Reduction From Baseline During Treatment | Dose Level 1b: 0.3 mg/kg | ≥ 50% reduction | 0 | Participants | |
| Number of Participants With Red Blood Cell Transfusion Burden Reduction From Baseline During Treatment | Dose Level 2: 0.5 mg/kg | ≥ 50% reduction | 1 | Participants | |
| Number of Participants With Red Blood Cell Transfusion Burden Reduction From Baseline During Treatment | Dose Level 3: 0.75 mg/kg | ≥ 50% reduction | 2 | Participants | |
| Number of Participants With Red Blood Cell Transfusion Burden Reduction From Baseline During Treatment | Dose Level 4: 1 mg/kg | ≥ 50% reduction | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01571635/results